Viking Therapeutics, Inc. (VKTX) Stock
Healthcare · Biotechnology · Member of Other US Stocks
Viking Therapeutics, Inc. (VKTX) closed at USD 25.47 on 2026-10-14, a change of -27.1 % over the past year, with a market capitalization of USD 3.48B.
Viking Therapeutics, Inc. recent closing prices
| Date | Close (USD) |
|---|---|
| 2026-10-14 | 25.47 |
| 2026-10-13 | 26.65 |
| 2026-10-12 | 28.34 |
| 2026-10-09 | 28.51 |
| 2026-10-08 | 27.73 |
| 2026-10-07 | 28.54 |
| 2026-10-06 | 28.38 |
The most recent trading day is not shown. For full charts and indicators use the analysis page.
Viking Therapeutics, Inc. key figures
- Previous close
- USD 25.47 (2026-10-14)
- 1-year change
- -27.1 %
- Market cap
- USD 3.48B
- Enterprise value
- USD 2.7B
- P/E ratio (trailing)
- -5.70
- P/E ratio (forward)
- -6.28
- EPS (trailing)
- -4.80
- EPS (forward)
- -4.36
- PEG ratio
- n/a
- Price to book
- 7.82
- Revenue growth
- n/a
- Earnings growth
- n/a
- Dividend per share (trailing)
- 0.00
- Short ratio
- 3.66
- Employees
- 65
- Analyst consensus (third-party)
- strong_buy
Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Technical indicators and comparison
Show RSI, MACD, EMA, CCI and ADX for Viking Therapeutics, Inc. and compare it with other stocks.
Analyze VKTXAll Other US Stocks stocksStock-scoring.com provides this page for information only. It is not investment advice or a recommendation to buy or sell Viking Therapeutics, Inc. shares.